Structure Obesity Pill Results Rival Novo, Lilly Treatments (1)

Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.

Patients on Structure’s once-daily pill, called aleniglipron, lost about 15% of their body weight after 44 weeks, while those given a placebo added a few pounds, the company said on Monday. There was no weight-loss plateau, and nausea and vomiting were the most common side effects.

The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital Markets ...